Vet Med - Czech, 2025, 70(6):196-202 | DOI: 10.17221/6/2025-VETMED

Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditionsOriginal Paper

R Krejci1, P Trampus2, A Csagola2, T Szalai2, N Palmai2, A Toth2, N Terenyi2, Z Nagy2, NA Szeplaki2, G Somogyi2, T Barna2, E Rausch2, Z Penzes2, M Szaszko3, Z Lorincz3
1 Ceva Sante Animale, Libourne Cedex, France
2 Ceva-Phylaxia Zrt., Budapest, Hungary
3 TargetEx Biosciences Ltd., Dunakeszi, Hungary

Mycoplasma hyopneumoniae (M. hyo) and porcine circovirus type 2 (PCV-2) are major and widespread swine pathogens, both implicated in the porcine respiratory disease complex, which can lead to significant economic losses for pig producers. PCV-2d is currently the most prevalent genotype. Vaccination against these two pathogens helps mitigate their impact on pig health and performance. The use of ready-to-mix or ready-to-use (RTU) vaccines targeting PCV-2a or PCV-2a/b and M. hyo is a common practice. This study aimed to evaluate the efficacy of a novel RTU vaccine containing PCV-2d and M. hyo antigens under experimental conditions. Several challenge trials were conducted using PCV-2a, PCV-2b, PCV-2d, and M. hyo to assess the level of protection conferred against different PCV-2 genotypes and M. hyo, as well as to determine the duration of protection. This study demonstrated that the bivalent PCV-2/M. hyo vaccine induces both early and long-lasting protection against infections caused by M. hyo and PCV-2. In addition, cross-protection against the three major PCV-2 genotypes was confirmed.

Keywords: enzootic pneumonia; PCV-2 disease; vaccination

Received: January 24, 2025; Revised: May 26, 2025; Accepted: May 27, 2025; Published: June 30, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krejci R, Trampus P, Csagola A, Szalai T, Palmai N, Toth A, et al.. Efficacy of a new ready-to-use vaccine against PCV-2d and Mycoplasma hyopneumoniae under experimental conditions. Vet Med - Czech. 2025;70(6):196-202. doi: 10.17221/6/2025-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ahn Y, Yang S, Oh T, Park KH, Cho H, Suh J, Chae C. Efficacy evaluation of a bivalent vaccine containing porcine circovirus type 2b and Mycoplasma hyopneumoniae against an experimental dual challenge. Front Vet Sci. 2021 Apr30;8:652313. Go to original source... Go to PubMed...
    2. Bandrick M, Balasch M, Heinz A, Taylor L, King V, Toepfer J, Foss D. A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines. Vet Res. 2022 Feb 18;53(1):12. Go to original source... Go to PubMed...
    3. Fachinger V, Bischoff R, Jedidia SB, Saalmuller A, Elbers K. The effect of vaccination against porcine circovirus type 2 in pigs suffering from porcine respiratory disease complex. Vaccine. 2008 Mar 10;26(11):1488-99. Go to original source... Go to PubMed...
    4. Franzo G, Segales J. Porcine circovirus 2 genotypes, immunity and vaccines: Multiple genotypes but one single serotype. Pathogens. 2020 Dec 14;9(12):1049. Go to original source... Go to PubMed...
    5. Ham S, Suh J, Oh T, Kim C, Seo BJ, Chae C. Efficacy of a novel bivalent vaccine containing porcine circovirus type 2d and Mycoplasma hyopneumoniae against a dual PCV2d and Mycoplasma hyopneumoniae challenge. Front Vet Sci. 2023 Jul 26;10:1176091. Go to original source... Go to PubMed...
    6. Huang L, Wang Y, Wei Y, Chen D, Liu D, Du W, Xia D, Wu H, Feng L, Liu C. Capsid proteins from PCV2a genotype confer greater protection against a PCV2b strain than those from PCV2b genotype in pigs: Evidence for PCV2b strains becoming more predominant than PCV2a strains from 2000 to 2010s. Appl Microbiol Biotechnol. 2016 Jul;100(13):5933-43. Go to original source... Go to PubMed...
    7. Kim J, Chung HK, Chae C. Association of porcine circovirus 2 with porcine respiratory disease complex. Vet J. 2003 Nov;166(3):251-6. Go to original source... Go to PubMed...
    8. Maes D, Sibila M, Kuhnert P, Segales J, Haesebrouck F, Pieters M. Update on Mycoplasma hyopneumoniae infections in pigs: Knowledge gaps for improved disease control. Transbound Emerg Dis. 2018 May;65(Suppl_1):110-24. Go to original source... Go to PubMed...
    9. Mancera Gracia JC, Smutzer M, Taylor L, Balasch M, Bandrick M. One dose of a novel vaccine containing two genotypes of porcine circovirus (PCV2a and PCV2b) and Mycoplasma hyopneumoniae conferred a duration of immunity of 23 weeks. Vaccines (Basel). 2021 Jul 29;9(8):834. Go to original source... Go to PubMed...
    10. Montane Giralt J, Simon-Grife M, Moros Sanz A, Puigvert Molas E, Gonzalez Gonzalez L, Pedernera Romano C, Acal Arias L, Sitja Arnau M. Duration of immunity of a novel intradermal vaccine against Mycoplasma hyopneumoniae and PCV2 infection. Abstract IMMPP-25. In: 12th European symposium of porcine health management; April 14-16, 2021; Bern (Switzerland); 2021; p. 493.
    11. Oh T, Suh J, Park KH, Yang S, Cho H, Chae C. A comparison of pathogenicity and virulence of three porcine circovirus type 2 (PCV2) genotypes (a, b, and d) in pigs singularly inoculated with PCV2 and dually inoculated with Mycoplasma hyopneumoniae and PCV2. Pathogens. 2021 Aug 3;10(8):979. Go to original source... Go to PubMed...
    12. Opriessnig T, Madson DM, Schalk S, Brockmeier S, Shen HG, Beach NM, Meng XJ, Baker RB, Zanella EL, Halbur PG. Porcine circovirus type 2 (PCV2) vaccination is effective in reducing disease and PCV2 shedding in semen of boars concurrently infected with PCV2 and Mycoplasma hyopneumoniae. Theriogenology. 2011 Jul 15;76(2):351-60. Go to original source... Go to PubMed...
    13. Opriessnig T, Thacker EL, Yu S, Fenaux M, Meng XJ, Halbur PG. Experimental reproduction of postweaning multisystemic wasting syndrome in pigs by dual infection with Mycoplasma hyopneumoniae and porcine circovirus type 2. Vet Pathol. 2004 Nov;41(6):624-40. Go to original source... Go to PubMed...
    14. Park C, Oh Y, Seo HW, Han K, Chae C. Comparative effects of vaccination against porcine circovirus type 2 (PCV2) and porcine reproductive and respiratory syndrome virus (PRRSV) in a PCV2-PRRSV challenge model. Clin Vaccine Immunol. 2013 Mar;20(3):369-76. Go to original source... Go to PubMed...
    15. Park C, Jeong J, Choi K, Chae C. Efficacy of a new bivalent vaccine of porcine circovirus type 2 and Mycoplasma hyopneumoniae (FosteraTM PCV MH) under experimental conditions. Vaccine. 2016 Jan 4;34(2):270-5. Go to original source... Go to PubMed...
    16. Park KH, Oh T, Yang S, Cho H, Kang I, Chae C. Evaluation of a porcine circovirus type 2a (PCV2a) vaccine efficacy against experimental PCV2a, PCV2b, and PCV2d challenge. Vet Microbiol. 2019 Apr;231:87-92. Go to original source... Go to PubMed...
    17. Pineyro P, Zhang J, Harmon K, Gauger P. PCV2 update: Pathogen, the disease and the diagnosis [Internet]. National Hog Farmer; 2020 [cited 2024 Dec 1]. Available from https://www.nationalhogfarmer.com/hog-health/pcv2-update-pathogen-the-disease-and-the-diagnosis.
    18. Puig A, Bernal I, Sabate D, Ballara I, Montane J, Nodar L, Angelats D, Jorda R. Comparison of effects of a single dose of MHYOSPHERE® PCV ID with three commercial porcine vaccine associations against Mycoplasma hyopneumoniae (Mhyo) and porcine circovirus type 2 (PCV2) on piglet growth during the nursery period under field conditions. Vet Res Commun. 2022 Dec;46(4):1167-73. Go to original source... Go to PubMed...
    19. Segales J, Sibila M. Revisiting porcine circovirus disease diagnostic criteria in the current porcine circovirus 2 epidemiological context. Vet Sci. 2022 Mar 2;9(3):110. Go to original source... Go to PubMed...
    20. Sibila M, Guevara G, Cuadrado R, Pleguezuelos P, Perez D, Perez de Rozas A, Huerta E, Llorens A, Valero O, Perez M, Lopez C, Krejci R, Segales J. Comparison of Mycoplasma hyopneumoniae and porcine circovirus 2 commercial vaccines efficacy when applied separate or combined under experimental conditions. Porcine Health Manag. 2020 May 4;6:11. Go to original source... Go to PubMed...
    21. Sibila M, Rocco C, Franzo G, Huerta E, Domingo M, Nunez JI, Segales J. Genotyping of porcine circovirus 2 (Pcv-2) in vaccinated pigs suffering from pcv-2-systemic disease between 2009 and 2020 in Spain. Pathogens. 2021 Aug 12;10(8):1016. Go to original source... Go to PubMed...
    22. Suh J, Oh T, Chae C. An evaluation of intradermal all-in-one vaccine based on an inactivated recombinant Mycoplasma hyopneumoniae strain expressing porcine circovirus type 2 (PCV2) capsid protein against Korean stains of PCV2d and M. hyopneumoniae challenge. Comp Immunol Microbiol Infect Dis. 2022 Nov-Dec;90-91:101911. Go to original source... Go to PubMed...
    23. Wei R, Xie J, Theuns S, Nauwynck HJ. Changes on the viral capsid surface during the evolution of porcine circovirus type 2 (PCV2) from 2009 till 2018 may lead to a better receptor binding. Virus Evol. 2019 Aug 1;5(2):vez026. Go to original source... Go to PubMed...
    24. Weissenbacher-Lang C, Kristen T, Mendel V, Brunthaler R, Schwarz L, Weissenbock H. Porcine circovirus type 2 (PCV2) genotyping in Austrian pigs in the years 2002 to 2017. BMC Vet Res. 2020 Jun 15;16(1):198. Go to original source... Go to PubMed...
    25. Witvliet M, Holtslag H, Nell T, Segers R, Fachinger V. Efficacy and safety of a combined Porcine Circovirus and Mycoplasma hyopneumoniae vaccine in finishing pigs. Trials Vaccinol. 2015 Dec;4:43-9. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content